Detalles de la búsqueda
1.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Lancet HIV
; 11(2): e75-e85, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38141637
2.
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014.
J Acquir Immune Defic Syndr
; 92(2): 153-161, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36215957
3.
Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014.
J Pediatric Infect Dis Soc
; 12(12): 602-609, 2023 Dec 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37815035
4.
Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients.
Antimicrob Agents Chemother
; 56(6): 3101-6, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22430964
5.
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.
Lancet Infect Dis
; 11(12): 907-15, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21933752
6.
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.
J Acquir Immune Defic Syndr
; 52(3): 350-6, 2009 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19648823
Resultados
1 -
6
de 6
1
Próxima >
>>